首页> 外文期刊>中华医学杂志(英文版) >First line nucleos(t)ide analog monotherapy is more cost-effective than combination strategies in hepatitis B e antigen-positive chronic hepatitis B patients in China
【24h】

First line nucleos(t)ide analog monotherapy is more cost-effective than combination strategies in hepatitis B e antigen-positive chronic hepatitis B patients in China

机译:在中国乙型肝炎e抗原阳性的慢性乙型肝炎患者中,一线核苷酸(t)ide类似物单药治疗比联合策略更具成本效益

获取原文
获取原文并翻译 | 示例
           

著录项

  • 来源
    《中华医学杂志(英文版)》 |2019年第19期|2315-2324|共10页
  • 作者单位

    Hepatology Unit Department of Infectious Diseases Nanfang Hospital Southern Medical University Guangzhou Guangdong 510515 China;

    Health Economics Research Institute Sun Yat-Sen University Guangzhou Guangdong 510085 China;

    Department of Epidemiology and Biostatistics School of Public Health Xi'an Jiao Tong University Health Science Center Xi'an Shaanxi 710061 China;

    Liver Research Center Beijing Friendship Hospital Capital Medical University Beijing 100050 China;

    School of Public Health Peking University Beijing 100191 China;

    School of Public Health Xi'an Jiao Tong University Health Science Center Xi'an Shaanxi 710061 China;

  • 收录信息 中国科学引文数据库(CSCD);
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号